- Home
- NVRI vs PRTC Comparison
NVRI vs PRTC Comparison
Compare NVRI & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVRI
- PRTC
- Stock Information
- Founded
- NVRI 1853
- PRTC 2015
- Country
- NVRI United States
- PRTC United States
- Employees
- NVRI 13000
- PRTC N/A
- Industry
- NVRI Diversified Commercial Services
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- NVRI Miscellaneous
- PRTC Health Care
- Exchange
- NVRI Nasdaq
- PRTC Nasdaq
- Market Cap
- NVRI 572.2M
- PRTC 509.0M
- IPO Year
- NVRI N/A
- PRTC N/A
- Fundamental
- Price
- NVRI $7.14
- PRTC $21.78
- Analyst Decision
- NVRI Hold
- PRTC Buy
- Analyst Count
- NVRI 1
- PRTC 1
- Target Price
- NVRI $10.00
- PRTC $45.00
- AVG Volume (30 Days)
- NVRI 661.4K
- PRTC 4.2K
- Earning Date
- NVRI 10-31-2024
- PRTC 08-28-2024
- Dividend Yield
- NVRI N/A
- PRTC N/A
- EPS Growth
- NVRI N/A
- PRTC N/A
- EPS
- NVRI N/A
- PRTC N/A
- Revenue
- NVRI $2,086,473,000.00
- PRTC $468,000.00
- Revenue This Year
- NVRI $16.52
- PRTC N/A
- Revenue Next Year
- NVRI $0.21
- PRTC $139.60
- P/E Ratio
- NVRI N/A
- PRTC N/A
- Revenue Growth
- NVRI N/A
- PRTC N/A
- 52 Week Low
- NVRI $5.65
- PRTC $17.08
- 52 Week High
- NVRI $12.79
- PRTC $34.00
- Technical
- Relative Strength Index (RSI)
- NVRI 35.57
- PRTC 54.20
- Support Level
- NVRI $6.57
- PRTC $20.61
- Resistance Level
- NVRI $7.57
- PRTC $22.83
- Average True Range (ATR)
- NVRI 0.39
- PRTC 0.54
- MACD
- NVRI 0.05
- PRTC 0.00
- Stochastic Oscillator
- NVRI 44.53
- PRTC 52.04
About NVRI Enviri Corporation
Enviri Corp engages in providing a broad range of environmental services and related solutions. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company serves a diverse customer base by offering critical recycle and reuse solutions for their waste streams, enabling customers to address their complex environmental challenges.
About PRTC PureTech Health plc
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.